Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 1,000 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,000 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the completion of the sale, the director now directly owns 299,695 shares of the company’s stock, valued at approximately $14,984,750. The trade was a 0.33 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Pro-Dex Stock Down 0.3 %

Pro-Dex stock opened at $48.92 on Friday. The company has a market capitalization of $159.53 million, a PE ratio of 24.34 and a beta of 0.68. Pro-Dex, Inc. has a 12-month low of $16.84 and a 12-month high of $59.60. The firm’s fifty day moving average is $39.78 and its 200 day moving average is $38.99. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, sell-side analysts predict that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Ritholtz Wealth Management acquired a new stake in shares of Pro-Dex in the 4th quarter worth about $572,000. FMR LLC increased its holdings in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares in the last quarter. Finally, 683 Capital Management LLC purchased a new position in shares of Pro-Dex during the fourth quarter valued at approximately $739,000. 15.28% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Pro-Dex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.